Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Teva Pharma (TEVA) PT Raised to $11 at Cowen
August 5, 2020 1:04 PM EDTCowen analyst Ken Cacciatore raised the price target on Teva Pharma (NYSE: TEVA) to $11.00 (from $9.00) while maintaining a Market Perform rating.
The analyst commented, "Teva is performing as well as can be expected, with good cost reductions while still executing on the Austedo... More
